PTGDS and Parkinson disease: Although our studies do not address whether DP2 receptors or L-PGDS directly mediate the PGJ2 effects in the rat model, we propose that neuronal DP2 receptor antagonists and L-PGDS inhibitors could be novel drugs to prevent/diminish PD pathology associated with neuroinflammation (Fig. 9).